Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T21:23:22.244Z.
Calculation as of: 2026-10-06T21:23:22.244Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69957a8c264286ff6eaa706b48c8270e863bf40c8b9bfd4321b5f2d082882a11
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$214.24M
EBITDA Yield
6.96%
TTM Avg
4.54%
3Y Avg
3.13%
5Y Avg
3.13%
Market Cap
$215.07M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$216.91M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$218.30M
EBITDA Yield
N/A
TTM Avg
143.11%
3Y Avg
143.11%
5Y Avg
143.11%
Market Cap
$210.41M
EBITDA Yield
N/A
TTM Avg
11.62%
3Y Avg
10.33%
5Y Avg
10.33%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | $214.46M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 6.96% | 4.54% | 3.13% | 3.13% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | N/A | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | N/A | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | N/A | 143.11% | 143.11% | 143.11% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | N/A | 11.62% | 10.33% | 10.33% |
| Compugen Ltd. (CGEN)vs › | $209.91M | N/A | 17.11% | 12.89% | 12.89% |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
| Profound Medical Corp. (PROF)vs › | $220.93M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
